Trial Profile
A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary) ; Carboplatin; Doxorubicin liposomal; Paclitaxel; Topotecan
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 28 Dec 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.